Biogen: Parkinson Disease trials

The registry lists 10 Parkinson Disease studies with Biogen as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 6Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleTerminatedNCT05418673Phase 3Results posted
• Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's DiseaseTerminatedNCT03318523Phase 2Results posted
• A Study to Evaluate SAGE-217 in Participants With Parkinson's DiseaseCompletedNCT03000569Phase 2Results posted
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80CompletedNCT05348785Phase 2
• Study to Evaluate DNL151 in Subjects With Parkinson's DiseaseCompletedNCT04056689Phase 1
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's DiseaseTerminatedNCT03716570Phase 1
• Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's DiseaseCompletedNCT02459886Phase 1
• BIIB014 Phase 2a MonotherapyWithdrawnNCT00451815Phase 2
• Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's DiseaseCompletedNCT00442780Phase 2
• Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's DiseaseCompletedNCT00438607Phase 2